Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 10;12:2. doi: 10.1186/s12348-021-00278-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 12 — Correlation between FA, ICGA and visual field during corticosteroid treatment of MFC. This myopic patient presents with left eye photopsias, left decrease of visual acuity (VA) and the presence of a subjective left scotoma. FA (top left) only shows cicatricial FA lesions corresponding to cicatricial fundus lesions seen on fundus examination. ICGA (top middle) shows widespread hypofluorescent areas indicating fresh choriocapillaris lesions with corresponding visual field defects (top right). During corticosteroid therapy, practically no change is seen on FA, whereas ICGA signs of active disease progressively resolve together with visual field improvement (right column). (Reprinted from Diagnostics (Basel). 2021 May 24;11 (6):939. 10.3390/diagnostics11060939)